ANU Stock Chart & Stats
€1.79
€0.09(5.04%)
At close: 4:00 PM EDT
€1.79
€0.09(5.04%)
Day’s Range― - ―
52-Week Range€1.10 - €4.10
Previous CloseN/A
Volume0.00
Average Volume (3M)213.00
Market Cap
€3.17M
Enterprise Value€3.22
Total Cash (Recent Filing)€250.45K
Total Debt (Recent Filing)€15.07K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,816,565
10 Day Avg. Volume640
30 Day Avg. Volume213
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)€2.02M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityVery low reported debt reduces financial risk and preserves optionality for a clinical-stage biotech. Over the next 2–6 months this structural low leverage supports ability to raise project financing or take on targeted debt without immediate solvency pressure, aiding program continuity.
Improving Loss TrajectoryMaterial narrowing of operating losses indicates tangible progress managing development costs and operational efficiency. Sustained improvement in burn-rate dynamics can extend runway, reduce near-term financing needs, and make the company a more viable partner for collaborations over the medium term.
Focused Clinical-stage PipelineA concentrated pipeline targeting kidney and metabolic disorders builds domain expertise and allows resources to be focused on high-conviction programs. In 2–6 months a clear clinical focus supports value-accretive partnerships, targeted trial design, and potential regulatory engagement that are durable strategic strengths.
Bears Say
No Product RevenueThe absence of recurring product revenue means the company must rely on external financing to fund R&D and trials. Over the medium term this structural dependence increases dilution risk, creates funding uncertainty for multi-stage trials, and limits self-sustaining growth prospects.
Shrinking Equity BaseA markedly reduced equity cushion weakens the company’s capital resilience and its ability to absorb setbacks or pursue parallel development programs. This structural erosion increases reliance on dilutive financings or partnerships, potentially constraining strategic flexibility over coming quarters.
Persistent Negative Cash FlowSustained negative operating and free cash flow, with recent deterioration in free cash flow growth, signals the company currently lacks internal cash generation. This structural shortfall limits ability to self-fund trials, increases refinancing risk, and may force prioritization of programs over the next 2–6 months.
XORTX Therapeutics Inc News
ANU FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was €1.09 and its highest was €4.10 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is €3.17M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 90 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:ANU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.